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Background. Visceral leishmaniasis (VL) caused by Leishmania infantum is endemic in the Mediterranean area. In the last decades
a northward spread of the parasite has been observed in Italy. This paper describes a VL outbreak in Modena province (Emilia-
Romagna, Northern Italy) between 2012 and 2015. Methods. Retrospective, observational study to evaluate epidemiological,
microbiological characteristics, and clinicalmanagement ofVL in patients referring to PoliclinicoModenaHospital.Results. Sixteen
cases of VL occurred in the study period. An immunosuppressive condition was present in 81.3%. Clinical presentation included
anemia, fever, leukopenia, thrombocytopenia, and hepatosplenomegaly. Serology was positive in 73.3% of cases, peripheral blood
PCR in 92.3%, and bone marrow blood PCR in 100%. Culture was positive in 3/6 cases (50%) and all the isolates were identified as
L. infantum by ITS1/ITS2 sequencing. The median time between symptom onset and diagnosis was 22 days (range 6–131 days). All
patients were treated with liposomal amphotericin b. 18.8% had a VL recurrence and were treated with miltefosine. Attributable
mortality was 6.3%. Conclusions. VL due to L. infantum could determine periodical outbreaks, as the one described; thus it is
important to include VL in the differential diagnosis of fever of unknown origin, even in low-endemic areas.
1. Introduction
Visceral leishmaniasis (VL) is a protozoan disease caused by
members of the Leishmania donovani complex and transmit-
ted by phlebotomine sand flies. VL primarily affects the host’s
reticuloendothelial system and, without treatment, it can be
a life-threatening disease. Symptoms include pancytopenia,
fever, and hepatosplenomegaly.
VL is endemic in southern Europe in the Mediterranean
area, where it is caused by L. infantum and the transmission
is mainly zoonotic [1]. However, new foci sustained by exotic
Leishmania species were recently reported in Europe, such
as L. donovani in Cyprus [2]. Furthermore, two cases of L.
major/L. infantum hybrids in HIV-positive injecting drug
users were detected in Portugal [3]. Therefore, monitoring
of species circulating in a given region, by either zymodeme
analysis or DNA-based typing, should be integrated into an
effective surveillance system.
In Italy, the Tyrrhenian littoral, the southern peninsu-
lar regions, and the islands have been considered classical
endemic zones for VL. Since the early 1990s, however, a
northward spread of the disease to previously nonendemic
Italian regions has been observed both in humans and in dogs
[4–6]. In particular, Biglino et al. showed a seroprevalence of
7.4% in asymptomatic healthy adults in Piedmont Region [5],
while Varani et al. reported a little outbreak of autochthonous
human VL cases in the Emilia-Romagna region [6].
In this paper we describe a VL outbreak, which took
place in the Modena province (Emilia-Romagna, Northern
Italy) between 2012 and 2015, focusing on its clinical and
microbiological characteristics.
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2. Materials and Methods
2.1. Design. We conducted a retrospective, observational
study including all patients with a VL diagnosis referring to
PoliclinicoModena Hospital from January 2012 to December
2015. We excluded patients living outside Modena province.
Epidemiological, clinical, and microbiological features of VL
cases were evaluated.
2.2. Case Definitions. VL case was defined according to
World Health Organization (WHO) criteria that include the
presence of VL clinical symptoms (mainly prolonged irregu-
lar fever, splenomegaly, andweight loss)with serologic and/or
parasitological confirmation (direct microscopy demonstra-
tion of Leishmania amastigotes, positive Leishmania spp.
polymerase chain reaction (PCR), or culture) [7, 8].
Hemophagocytic syndrome was defined according to
literature criteria [9].
VL recurrence was defined as a new onset of VL signs and
symptoms associated with positivity of Leishmania spp. PCR
after a negative sample in the 6-month follow-up period.
2.3. Laboratory Diagnostic Methods. Anti-L. infantum anti-
bodies were assayed using an indirect immunofluorescence
test (Leishmania Spot-IF; bioMerieux,Marcy l’Etoile, France)
and titers were considered significant if equal or above 1 : 80.
DNA in peripheral and in bone marrow blood was
investigated using a nested-PCR performed as described
elsewhere [10]. Both immunofluorescence assay tests and
molecular methods were performed in the Microbiology
Laboratory of Policlinico Modena Hospital.
Bone marrow aspirates were inoculated into Evans’ mod-
ified Tobie’s medium. Cultures were maintained at 25∘C;
the supernatant was examined for parasite growth by light
microscopy every three days and subcultured once a week for
4 weeks before they were reported as negative. Positive cul-
tures were transferred to RPMI-1640 supplemented with 10%
fetal calf serum for mass culturing. To identify Leishmania
species, the ribosomal internal transcribed spacers ITS1 and
ITS2 were amplified and sequenced as previously described
[10]. To each isolate, ITS genotype was assigned according to
the number of variable repeats of the 12 microsatellite regions
in ITS1 (four sites) and in ITS2 (eight sites). Sequences
obtained were aligned using the CLUSTAL W application
of BioEdit version 7.0.8.0. and compared with the sequences
described by Kuhls et al. [11].
For morphologic assessment, bone marrow smears were
stained with May-Gru¨nwald-Giemsa and examined under
the light microscope at high magnification. The microscopic
evaluation was considered positive in presence of Leishmania
amastigotes, either intomacrophage cytoplasms or dispersed.
2.4. VL Treatment. All patients included in the study were
treated with liposomal amphotericin B (L-AmB), with a total
dose of 40mg/kg for HIV-infected patients and 20mg/kg for
all the others according to international guidelines [7, 12, 13].
In particular, patients with HIV infection received 4mg/kg
once daily on days 1–5, 10, 17, 24, 31, and 38; HIV-negative
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Figure 1: Visceral leishmaniasis incidence per 100,000 inhabitants
in 2008–2015 period in the Modena province.
patients received 3mg/kg of L-AmBonce daily on days 1–5, 14,
and 21. Patients with VL recurrence in the follow-up period
were treatedwithmiltefosine 50mgTID for 28 days. No short
course treatment was performed.
2.5. DataCollection and Statistical Analysis. Epidemiological,
clinical, microbiological, and treatment characteristics were
collected. All patients included in the study had a six-month
follow-up period.
Due to the small number of patients enrolled, we per-
formed only a descriptive statistical analysis expressing cat-
egorical and continuous variables as frequency (percentage)
and median values (range values).
On the basis of calendar date of diagnosis and annual
epidemiological data of Modena population [14], incidence
rates of VL were calculated.
All statistical analyses have been performed using STATA
13 for Windows (StataCorp ltd., College Station, TX).
2.6. Ethics Statement. A corresponding approval from the
Modena ethic committee was obtained. The study was per-
formed in accordance with the ethical standards laid down in
the 1964 Declaration of Helsinki and its later amendments.
Due to the retrospective nature of this study the informed
consent was waived. Clinical samples were collected during
routine diagnosis and/or follow-up, including no additional
invasive procedures. Patient records were anonymized prior
to analysis.
3. Results
From January 2012 to December 2015, 16 new cases of VL
occurred in Modena province (3 patients in 2012, 5 in 2013,
7 in 2014, and 1 patient in 2015). The incidence per 100,000
inhabitants was 0.43 in 2012, 0.71 in 2013, 0.99 in 2014, and
0.14 in 2015. Figure 1 describes VL incidence in the calendar
years from 2008 to 2015 in the Modena province [15].
The majority of patients were resident in rural and hilly
areas. Figure 2 describes VL case distribution. None of the
patients have been in endemic areas for human VL in the five
years before diagnosis.
81.3% were males (13/16), median age was 63 years
(range 33–83 years), and 81.3% had one (9/16) or two (4/16)
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Figure 2: Human visceral leishmaniasis cases distribution map
according to residency in Modena province (adapted with permis-
sion from www.italomairo.com) from 2012 to 2015. The darkest
zones represent the Emilian Apennines.
immunosuppression conditions. In particular, four out of 16
patients (25%) were on chronic steroid therapy, three (18.8%)
were HIV-positive, three (18.8%) had a hematologic disease,
three (18.8%) had a neoplastic disease, one (6.3%) was an
injective drug user, and one (6.3%) was cirrhotic.
Table 1 shows clinical picture at VL diagnosis and micro-
bial tests used for diagnosis of Leishmania spp.
The majority of patients (13/16, 81.3%) presented symp-
toms in autumn/winter. At admission signs and symptoms
were fever (15/16, 93.8%), splenomegaly (13/16, 81.3%), asthe-
nia (12/16, 75%), hepatomegaly (11/16, 68.8%), weight loss
(6/16, 37.5%), and abdominal lymphadenomegaly (4/16, 25%).
Biochemical findings were anemia (16/16, 100%), leukope-
nia (14/16, 87.5%), thrombocytopenia (13/16, 81.3%), ALT
value > 2x upper limit of normal values (7/16, 43.8%), and
hemophagocytic syndrome (4/16, 25%). Median baseline
creatinine was 1mg/dL (range 0.8–1.3).
In total, 15 patients performed a serology, 13 patients
a peripheral blood PCR, and 12 patients a bone marrow
PCR; 6 patients had a culture sample and 11 patients a bone
marrowmicroscopic examination. 11/15 patients (73.33%) had
a positive serology and patient 8 had a borderline titer of
1 : 40. Patient 8 was cirrhotic and this could justify the low
serologic titer we found. All but one peripheral blood PCR
were positive (92.31%), while all the bone marrow PCRs were
positive (100%).Threemicroscopic examination out of eleven
(27.27%) demonstrated the presence of amastigotes.
Patient 14 had only a positive serologywhile nomolecular
procedures were performed before treatment. The patient
was admitted to the hospital with asthenia, anorexia, and
hepatosplenomegaly. The biochemical exams showed the
presence of pancytopenia and hyperferritinemia. After VL
treatment all the signs and symptoms gradually solved as did
blood exams. Since the patient had the presence of VL clinical
symptoms with serologic confirmation we decided to include
her in the analysis (Table 1).
The culture was positive in 3/6 cases. All the isolates were
identified as L. infantum by the analysis of the 12 microsatel-
lite sites of the ITS1 and ITS2 concatenated sequences [11].
The median time between symptoms onset and hospital
admission was 14.5 days (range 4–125 days).Themedian time
between symptoms onset and diagnosis was 22 days (range
6–131 days). The median time between hospital admission
and diagnosis was 6 days (range 2–21), with no significant
variations during calendar years of the study period.
All patients included in the study were treated with L-
AmB as described before. Two patients (12.5%) had a VL
recurrence in the follow-up period, both 8 weeks after the
first administration of L-AmB. One of the two patients with
VL recurrence was on chronic steroid treatment; the other
one had a hematological disease. Miltefosine treatment led
to clinical and microbiological resolution. One patient died
(6.3%) 53 days after symptom presentation, 17 days after
diagnosis and starting treatment. He had alcoholic cirrhosis
as comorbidity. His death was attributable to VL. L-AmB cure
rate was 81.3%.
During treatment and follow-up, hematological and bio-
chemical alterations gradually resolved within two weeks as
shown in Figure 3. Of note, we did not observe any significant
increase of serum creatinine during the observation period
despite the use of L-AmB.
4. Discussion
Our study describes an outbreak of VL observed in Modena
province (Emilia-Romagna region, Northern Italy) from 2012
to 2015. We collected 16 new cases of VL in a confined area
with a peak of 0.99 cases per 100,000 inhabitants in 2014,
while the average number of cases per year before 2012 was
less than 0.2 cases per 100,000 inhabitants [15]. In 2015 the
incidence reduces again.
In the early 1970s a severe outbreak of VL was reported
in Emilia-Romagna, with a similar distribution of cases, in
particular in the foothills of the Apennines zone. However
this focus was considered atypical and no further cases were
reported in the following 15 years [16].
Although the southern peninsular Italian regions and the
islands have been considered classical endemic areas for VL
[4], starting from 1990s, also northern continental Italian
regions have become focally endemic for L. infantum as
shown through active surveillance in dogs and phlebotomine
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Figure 3: Biochemical trends during visceral leishmaniasis treat-
ment (median values). BL: baseline; PLT: platelets; WBC: white
blood cells; ALT: alanine aminotransferase; HB: haemoglobin.
sand flies [17].With regard to humanVL, the ItalianMinistry
ofHealth reported 230VL cases among residents inNorthern
Italy (10.9% of all Italian cases) from 1990 to 2005, mainly
fromLombardy (109 cases), Piedmont (42 cases), and Emilia-
Romagna (25 cases) [17].
Modena province is a central area of Emilia-Romagna
(North-Eastern Italy) (Figure 2), with a mean population
of 704,364 inhabitants during the study period [14]. The
province covers an area of 2,688 km2 and approximately
half of it, in its northern part, consists of the Po valley
plains, while the remaining part of the province is covered
by hills and mountains up to 2,165m above sea level. Climate
is subcontinental, with a mean temperature of 12.4∘C and
mean annual precipitations of 764mm [18]. The Po plain,
which covers the 48% of the study area, is mainly occupied
by agriculture and artificial areas. Hilly and mountainous
areas cover the remaining 17% and 35% of the province,
respectively, with a prevalence of natural and seminatural
areas.
Previous entomological surveys have established the
presence of two proven vectors of L. infantum in Emilia-
Romagna: Phlebotomus perfiliewi and P. perniciosus [16, 17].
Sand flies are mainly distributed in the hilly areas of the
region, including the neighbouring area between Modena
and Bologna provinces. P. perfiliewi represents the most
abundant species [19] and it is considered a less efficient
vector of L. infantum [17] in comparison to P. perniciosus.
However, Baldelli et al. [20] reported a canine leishmaniasis
focus sustained by P. perfiliewi and its role in the VL
transmission also cannot be excluded.
Our results show an increase of the median number of
VL per year starting from 2012 with a decrease in 2015.
Anamnestic information, microbiological data, and the pres-
ence of competent vectors, combined with previous sporadic
reports of the disease in the Modena province [16], suggest
the presence of an autochthonous stable focus of L. infantum
in the study area, characterized by a recent upsurge. During
the same period, Varani et al. reported a VL outbreak in the
neighbouring Bologna province, Emilia-Romagna, with 14
cases diagnosed in six months [6].
The reasons of the leishmaniasis reemergence in Emilia-
Romagna are not definitely known. With regard to dogs,
recognized as primary reservoir hosts of zoonotic VL, any
important changes in the canine leishmaniasis epidemiology
were observed. Results of a multiyear surveillance program
carried out in public kennels of Emilia-Romagna showed
an increase in canine leishmaniasis seroprevalence from
2010 (1%) to 2012 (2.4%) [19]. Afterwards a slight decrease
was observed [21], with prevalence values lower than those
observed in traditionally endemic regions of central and
southern Italy [4].
Even though climate change might affect leishmaniasis
distribution both directly and indirectly, the association
between the two has been only surmised, with lack of
definitive evidence [17, 22]. It is demonstrated that from 2000
to 2009 the median annual temperature in Italy increased by
0.8 Celsius degrees compared to the previous decade but no
more recent data are available [23].
Further investigations involving multidisciplinary
researchers should be carried out in Emilia-Romagna in
order to address important epidemiological questions.
Studies should be focused on environmental and climate
factors influencing the exposure to sand fly bites. Considering
that clinical VL cases usually represent the tip of an “infection
iceberg,” the prevalence of asymptomatic human carriers
and triggers of clinical disease should also be evaluated.
Even though L. infantum is the causative agent of VL
in Italy, molecular typing with more discriminant tools and
characterization of additional isolates could contribute to
better understanding the transmission dynamics between
humans, vectors, and animal reservoirs as suggested by
Chicharro et al. [24].
Due to the increasing incidence of VL in the last years,
we expected to find an improvement in our capability to
diagnose VL. In the majority of cases the clinical suspicion
is the keystone for a rapid diagnosis and, consequently, a
rapid treatment and a better prognosis. Actually, we found
no difference in the median time between onset of symptoms
and diagnosis in the five years considered in our study.
The clinical characteristics at presentation in our cohort
did not differ from the literature, anemia, fever, leukopenia,
thrombocytopenia, and hepatosplenomegaly being the most
frequent symptoms and signs at diagnosis. Thus, being to
include VL in the differential diagnosis of fever of unknown
origin.
HIV infection is known to be one of the most important
risk factors for VL. Nevertheless, only a small percentage
of our patients were HIV-positive while we noticed an
important presence of other immunosuppression causes (e.g.,
chronic steroid therapy, hematologic/neoplastic disease, and
cirrhosis), recently associated with the onset of VL [25–27].
With the improvement in treatment strategies for hemato-
logical and rheumatological diseases (e.g., patients receiving
biological agents [28]), we will probably observe a higher
6 BioMed Research International
number of immunosuppressed patients; thus it is important
for clinicians to consider also VL in the differential diagnosis
of infections.
In our experience, PCR, both on peripheral and on bone
marrow blood, is a sensitive technique for diagnosis of VL
with 92.3% and 100% of positive samples, respectively. A
positive PCR on peripheral blood in a patient with clinical
suspicion of VLwas sufficient for VL diagnosis and permitted
us to avoid bone marrow aspiration in different cases. On
the contrary, a negative PCR on peripheral blood in a
patient with high clinical suspicion of VL necessitates further
investigations in order to exclude VL diagnosis.
Regarding treatment, we followed WHO recommenda-
tions for VL due to L. infantum, based on regional differences
and expert opinions [7, 12]. We did not explore short course,
high dose regimens such as single dose L-AmB. In our study,
standard doses of L-AmB showed a good cure rate and profile
of tolerability.
Our study has some limitations: first of all the limited
number of cases did not allow us to derive definitive con-
clusions on sensitivity or specificity of the single diagnostic
approach; secondwe had only cases in adult patients; thus our
findings could not be taken as evidence in children. Finally,
the majority of patients in the study presented an underlying
immunosuppressive condition; although no one reported
anamnestic VL diagnosis, it was not possible to completely
exclude reactivation episodes instead of acute illnesses. A
routine serologic test for VL in immunosuppressed patients
could be implemented.
5. Conclusions
VL due to L. infantum could determine periodical outbreaks;
thus it is important to include VL in the differential diag-
nosis of fever of unknown origin, even in low-endemic
areas, especially if pancytopenia and/or hepatosplenomegaly
are present. Since the reasons of leishmaniosis periodic
reemergence in the Emilia-Romagna region are not definitely
known, multidisciplinary epidemiological and molecular
studies are needed, in order to elucidate gaps in epidemio-
logical aspects.
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